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On 19 February 2014, Inkatha Freedom Party MP 
Mario Oriani-Ambrosini made an impassioned plea 
to President Zuma and the South African (SA) 
government to legalise the medical use of cannabis 
and informed Parliament that he was introducing 
a private member’s bill, the Medical Innovation Bill, to move this 
agenda forward.[1] The President responded by indicating that he had 
asked the Minister of Health to look into the matter.
Medical cannabis refers to the use of cannabis and its constituent 
cannabinoids, including Δ(9)-tetrahydrocannabinol (THC) and 
cannabidiol (CBD), as therapy to treat or alleviate symptoms of medical 
conditions. In some countries synthetic cannabinoids, such as nabilone 
(Cesamet) and dronabinol (Marinol), are available for these purposes. 
Cannabinoids are delivered through various mechanisms, the most 
obvious being through smoking. However, smoking cannabis can 
be hazardous to health over the long term because toxic compounds 
are created in the combustion process. In addition, it is difficult to 
regulate the amount of cannabinoids being ingested. However, users 
report that smoking relieves symptoms quickly. Cannabinoids can 
also be ingested orally, inhaled through vapourisers (Nabidiolex), and 
used transdermally and via suppositories. Synthetic cannabis is most 
often delivered in pill form. Obviously these delivery mechanisms vary 
in cost and ease of access. In SA, smoking is the cheapest and most 
easily accessible delivery mechanism as cannabis is widely available 
to purchase, though not without risk of arrest. Cannabis oil is also 
available on the black market, and there are recipes on the internet for 
people seeking to make their own.[2]
Medical use of cannabis is now legal in Austria, Canada, Finland, 
Germany, Israel, Italy, the Netherlands, Portugal and Spain. 
Furthermore, medical users of cannabis in 20 states and the District 
of Columbia in the USA are not prosecuted as long as they are in 
compliance with the state’s marijuana sale regulations. In contrast, it 
is currently illegal to possess cannabis or trade in it in SA.[3] We also 
have no medications approved by the Medicines Control Council that 
contain THC, other cannabinoids or even synthetic cannabinoids.[4] 
Cannabis has also not been approved for medical use by the US Federal 
Drug Administration, largely as a result of three shortcomings: (i) the 
lack of human clinical trials to show that the benefits outweigh the risks; 
(ii) inconsistencies in the main chemical compound, particularly when 
smoked; and (iii) the negative health effects sometimes associated with 
cannabis use, particularly when smoked.[5] Any decisions on legalising 
the medical use of cannabis must take into consideration the risk of 
possible harms that have been demonstrated among some people who 
regularly use cannabis, the possible effects that legalising medical use 
of cannabis may have on the non-medical use of the drug, possible 
impacts on communities and broader society, and the quality of the 
evidence supporting the medical use of cannabis.
Harms associated with cannabis use
On the first issue, our own research has shown associations between 
cannabis use and road traffic injuries and other forms of trauma,[6] 
crime, particularly property crime and murder,[7] and sexual HIV risk 
behaviours,[8] but the causal mechanisms were not clearly elucidated. 
Unpublished research conducted in SA using functional magnetic 
resonance imaging also showed cognitive deficits associated with cannabis 
use, even after participants had stopped using cannabis for several weeks 
(Carey P, et al. – ‘Functional magnetic resonance imaging (f-MRI) of 
abstinent cannabis, cannabis/methaqualone users, and normal controls’, 
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presented at the 6-monthly meeting of the South African Community 
Epidemiology Network on Drug Use, 16 November 2005). In addition, 
a recent systematic review identified several adverse effects associated 
with cannabis use, including a dependence syndrome, an increased risk 
of motor vehicle crashes, impaired respiratory function, cardiovascular 
disease, and adverse effects of regular use on adolescent psychosocial 
development and mental health.[9] However, these harms should not be 
overstated, as they do not affect all people who use cannabis. Certainly, 
at a community level the harms are a lot fewer than those associated with 
alcohol and tobacco use.[10,11]
Impact of medical cannabis use on 
non-medical use
On the second issue, very few studies have examined whether 
allowing medical use of cannabis impacts on its non-medical use. A 
large study investigating the relationship between state legalisation 
of medical cannabis and cannabis use, abuse and dependence in the 
USA found that states that legalised medical cannabis had higher 
rates of use, but the authors acknowledged that this association was 
not necessarily causal.[12] National surveys in Canada have indicated 
substantial use of cannabis for therapeutic purposes outside of the 
Health Canada programme, with an order of magnitude of between 
13 and 33 persons for every one person in the programme.[13]
Quality of the evidence supporting 
medical use of cannabis
The third important issue when considering whether to legalise the 
medical use of cannabis is the quality of the evidence in support of 
its effects on medical conditions. In his speech in Parliament, Oriani-
Ambrisoni referred to studies from Harvard cited in a Cannabis 
Position Paper presented to the Central Drug Authority in November 
2013.[14] This paper highlights various studies, mainly preclinical 
but some involving human subjects, that showed positive effects on 
a variety of conditions including Alzheimer’s disease, amyotrophic 
lateral sclerosis, chronic pain, multiple sclerosis, diabetes mellitus, 
dystonia, fibromyalgia, incontinence, gastrointestinal disorders and 
various cancers, including lung cancer, the condition affecting Oriani-
Ambrisoni. Other conditions that have reportedly been positively 
affected by cannabis use include atopic dermatitis, brain injuries, eating 
disorders, epilepsy, glaucoma, Huntington’s disease, neuromuscular 
disorders, rheumatoid arthritis, sleep disorders and Tourette’s syn-
drome, though in many cases the supportive evidence is equivocal.[15]
Cannabinoids are used for symptom management in cancer, while 
there is emerging evidence that cannabinoids may have anticancer 
effects, particularly antitumour effects.[16] However, few human 
clinical trials have been published in this area, and more trials are 
required to achieve certainty that cannabis or cannabinoids can be 
used as anticancer agents.[16] With regard to pain relief in cancer 
patients, in experimental models of acute pain, inhaled cannabis 
resulted in dose-dependent pain relief. In patients with chronic pain, 
both cannabis and cannabinoids outperformed placebo treatment. 
However, few studies have compared cannabis or cannabinoids with 
conventional medications used to manage pain in cancer.[16]
The effects of cannabis or cannabis extracts on AIDS wasting 
syndrome or weight loss from AIDS have been studied, mainly 
because cannabis or cannabinoids reportedly stimulate the appetite. A 
Cochrane review found that the seven studies included in the review 
suffered from bias and small sample size and lacked longitudinal 
data, limiting the extent to which conclusions could be drawn.[17] The 
evidence is stronger regarding the positive effect of cannabinoids 
in treating chemotherapy-induced nausea and vomiting in cancer 
patients.[16,18] Human studies suggest efficacy of cannabinoids in 
the management of chemically induced nausea and vomiting, but 
further research aimed at developing new endocannabinoid-based 
antinausea and antiemetic therapies is still warranted.[18]
Conclusions
There appears to be a divide between the reported medical benefits 
of cannabis use and well-executed studies on the benefits and risks of 
such use.[13] Although evidence from preclinical studies points to the 
potential for cannabinoids to contribute to symptom alleviation and 
possible effects on disease status for a number of medical conditions, 
there are significant gaps in our understanding of the potential 
benefits and risks associated with their use. Most notable is the lack 
of evidence from human trials. That said, and in line with part of 
the reasoning behind the proposed legislation,[1] the SA government 
should make it easier for researchers to conduct studies on the medical 
use of cannabinoids (including synthetic cannabinoids), and funding 
should be made available to support this research, especially where it 
could lead to medical innovation. This research should include: (i) an 
investigation of factors that led to the policy shifts in countries that 
have legalised the medical use of cannabis, and what their experiences 
have been of this policy shift; (ii) maintaining a watching brief on the 
literature in this area, as advances in scientific knowledge are taking 
place rapidly; (iii) establishing surveillance systems to assess the poss-
ible influences of medical cannabis use on non-medical cannabis use; 
and (iv) conducting both preclinical and human studies to study the 
effects of cannabinoids on symptom alleviation and disease status. 
For the latter, longitudinal studies that investigate the effects of 
cannabinoid inhalation and ingestion on the quality of life of patients 
with HIV/AIDS, where SA should lead the way, are especially needed.
In conclusion, while in principle we are open to the idea of 
cannabis use for medical conditions, we need to strengthen the 
empirical evidence base in support of the benefits of such use, and 
find ways to minimise the risk of harms, before we can recommend 
legalising medical cannabis use in SA.
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